COSCIENS Biopharma Inc (CSCI)

[cary73]

here there is no more trust you do not see the volume, the continuous decline ... the market knows very well that macrilen is not a good deal and that it will not bring any value here ... if it is approved in 2024 what do you think it is do you bring to the company? 3.4 million dollars which added to the 3 of adults make 7 million a year ... it's funny ... it's not even worth considering .... and the rest? only preclinical studies that will never see a sequel. This is the reality ... Gentlemen have been studying macrilen for over 15 years, spending millions and millions of dollars ... if there was value after all this time, don't you think it would have already been considered?
this is reality the rest are just dreams